貨號：GS40533

Patecibart is a humanized IgG4?kappa monoclonal antibody that specifically targets the endothelin A receptor (EDNRA), a G protein?coupled receptor. As an IgG4 isotype, it is engineered to minimize effector functions (e.g., antibody?dependent cellular cytotoxicity) and focus on receptor blockade. By binding to EDNRA with high affinity, patecibart antagonizes the interaction between the receptor and its ligand endothelin?1 (ET?1), thereby inhibiting downstream signaling pathways (e.g., Gq/11?mediated calcium mobilization, MAPK activation). This blockade aims to suppress ET?1/EDNRA?driven processes such as vasoconstriction, fibrosis, inflammation, and cell proliferation.